Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Status:
Withdrawn
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of veliparib when given together
with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has
spread to other places in the body and usually cannot be cured or controlled with treatment,
has returned after a period of improvement, and cannot be removed by surgery. Veliparib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs
used in chemotherapy, such as capecitabine and temozolomide, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading.